EPA and DHA for Dogs: How to Read a Fish Oil Label

The number of milligrams of fish oil on a dog supplement label is not the same as the amount of EPA and DHA it provides. Canine studies typically describe defined fatty-acid exposures, specific oils, or complete diets rather than treating “fish oil” as a single standardized dose.

That means a front-label number such as “1,000 mg fish oil” cannot, by itself, tell you whether a product resembles an intervention used in a dog study.

Key takeaways

• Fish oil is a source material; EPA and DHA are specific long-chain omega-3 fatty acids within it.
• Two products with the same total fish-oil mass can provide different EPA+DHA amounts.
• Dog trials often report EPA and DHA separately or as a combined exposure.
• Matching a study dose still does not make a retail product clinically equivalent to the studied intervention.
• Disease-specific research doses should not be copied automatically for general wellness use.

Fish oil, omega-3, EPA, and DHA are not the same number

A label may contain several different quantities:

• total fish oil;
• total omega-3 fatty acids;
• EPA;
• DHA;
• combined EPA+DHA.

These numbers answer different questions.

For scientific interpretation, EPA and DHA are often more useful than total oil mass because they are defined fatty acids that can be compared across studies.

A simple label example

Imagine two products each list 1,000 mg fish oil per serving.

One could provide a relatively low concentration of EPA and DHA; another could be much more concentrated. Without the EPA/DHA values, the front-label fish-oil number does not tell you how closely either product resembles a study intervention.

So:

1,000 mg fish oil ≠ 1,000 mg EPA+DHA

How canine studies report omega-3 exposure

A double-blind crossover study of canine pruritic skin disease used a marine-oil capsule containing 180 mg EPA and 120 mg DHA per 1 mL capsule, given according to body weight. That is a much more precise intervention description than “fish oil capsule.”

A randomized placebo-controlled trial in 29 dogs with atopic dermatitis used a commercial preparation providing 50 mg/kg/day EPA and 35 mg/kg/day DHA, while another group received flax oil and controls received mineral oil.

In osteoarthritis research, another placebo-controlled trial used an average of 69 mg EPA+DHA/kg/day.

The point is not that these amounts should be copied. The point is that evidence is tied to defined exposure and context.

Why total oil mass can mislead

Total fish-oil mass includes more than EPA and DHA. The proportion of EPA and DHA depends on the source and concentration process.

When two products list only total fish oil, you cannot assume they provide comparable amounts of the fatty acids most directly tied to the published intervention.

Why dose still does not prove efficacy

Even when a product provides the same nominal EPA+DHA amount used in a study, several other questions remain:

• Was the study in osteoarthritis, atopic dermatitis, pruritus, or another condition?
• Was the intervention an isolated oil or a complete therapeutic diet?
• Were other fatty acids or nutrients changed at the same time?
• Was the exact product formulation tested?

Dose matching is therefore an evidence-relevance check, not proof of efficacy.

Skin studies illustrate the problem

In the 29-dog atopic dermatitis trial, dogs receiving EPA+DHA or flax oil improved clinically, while placebo dogs did not. However, the investigators found no correlation between clinical scores and total fatty-acid intake or omega-6:omega-3 ratio.

A 60-dog randomized study of a borage-oil plus fish-oil combination examined whether supplementation could reduce prednisolone use. The overall prednisolone difference was not significant across the full test period, although a difference emerged in later time windows.

These studies show why a shopper cannot reduce the evidence to one simple “ideal fish-oil dose.”

What a useful label should tell you

For evidence interpretation, useful fields include:

• EPA per serving;
• DHA per serving;
• combined EPA+DHA;
• serving size;
• directions linked to body weight;
• source and formulation;
• other active ingredients.

What the evidence does not prove

A label with a high EPA+DHA number does not prove that:

• the product works clinically;
• more is always better;
• a skin-disease dose applies to joint disease;
• a disease-treatment study supports routine wellness use;
• the exact product has been clinically tested.

fish-oil mass ≠ EPA+DHA exposure ≠ proven clinical efficacy

Dog Supplement Facts evidence status

NOT_ASSESSED

This is an evidence-literacy article rather than a category efficacy review.

Related Dog Supplement Facts content

• Dog Skin & Coat Guide
• Fish Oil vs Allergy-Support Chews for Dogs
• How to Check a Dog Skin & Coat Supplement Label
• Dog Skin & Coat Comparison

References

1. Logas D, Kunkle GA. Marine oil supplementation containing high-dose eicosapentaenoic acid for canine pruritic skin disease. Veterinary Dermatology. 1994;5(3):99–104. PMID 34645070. doi:10.1111/j.1365-3164.1994.tb00020.x.
2. Mueller RS, Fieseler KV, Fettman MJ, et al. Effect of omega-3 fatty acids on canine atopic dermatitis. Journal of Small Animal Practice. 2004;45(6):293–297. PMID 15206474. doi:10.1111/j.1748-5827.2004.tb00238.x.
3. Saevik BK, Bergvall K, Holm BR, et al. Steroid-sparing effect of essential fatty acid supplementation in canine atopic dermatitis. Veterinary Dermatology. 2004;15(3):137–145. PMID 15214949. doi:10.1111/j.1365-3164.2004.00378.x.
4. Mehler SJ, May LR, King C, et al. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2016;109:1–7. PMID 27269707. doi:10.1016/j.plefa.2016.03.015.